LSE - Delayed Quote GBp

Celadon Pharmaceuticals Plc (CEL.L)

15.00
+1.00
+(7.14%)
At close: June 4 at 6:03:23 PM GMT+1
Loading Chart for CEL.L
  • Previous Close 14.00
  • Open 0.00
  • Bid 12.00 x --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 85.00
  • Volume 100,000
  • Avg. Volume 217,824
  • Market Cap (intraday) 10.327M
  • Beta (5Y Monthly) -0.11
  • PE Ratio (TTM) --
  • EPS (TTM) -0.08
  • Earnings Date Jun 5, 2025 - Jun 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

celadonpharma.com/

27

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CEL.L

View More

Performance Overview: CEL.L

Trailing total returns as of 6/4/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

CEL.L
0.00%
FTSE 100 (^FTSE)
7.69%

1-Year Return

CEL.L
81.93%
FTSE 100 (^FTSE)
6.92%

3-Year Return

CEL.L
85.58%
FTSE 100 (^FTSE)
16.84%

5-Year Return

CEL.L
88.46%
FTSE 100 (^FTSE)
38.79%

Compare To: CEL.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CEL.L

View More

Valuation Measures

Annual
As of 6/3/2025
  • Market Cap

    9.64M

  • Enterprise Value

    14.40M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    68.24

  • Price/Book (mrq)

    3.97

  • Enterprise Value/Revenue

    110.78

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.40%

  • Return on Equity (ttm)

    -190.71%

  • Revenue (ttm)

    130k

  • Net Income Avi to Common (ttm)

    -5.23M

  • Diluted EPS (ttm)

    -0.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16k

  • Total Debt/Equity (mrq)

    194.82%

  • Levered Free Cash Flow (ttm)

    -4.4M

Research Analysis: CEL.L

View More

Company Insights: CEL.L

Research Reports: CEL.L

View More

People Also Watch